Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
December 22nd 2017

Medical World News®, December 2017

AJMC Staff
Key drug approvals; alcohol cancer link.
Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017
December 22nd 2017

Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017

Jaime Rosenberg
Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.
Terrill Jordan: Year 1 Feedback on OCM
December 22nd 2017

Terrill Jordan: Year 1 Feedback on OCM

Based on CMMI's year 1 feedback on OCM, it is clear that a lot of planning is needed and education is crucial, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
5 Aspects of How Diet Does, and Does Not, Impact Health
December 22nd 2017

5 Aspects of How Diet Does, and Does Not, Impact Health

Laura Joszt, MA
For the most part, it’s well known that eating healthy and in moderation is more beneficial to our health. In 2017, there were a number of news stories that drove that knowledge home.
FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer
December 21st 2017

FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer

Jaime Rosenberg
The FDA's 2013 accelerated approval of pertuzumab for neoadjuvant use was converted to full approval as part of treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer.
Site Logo
December 20th 2017

Will 2-Sided Risk Be a Reality in the OCM?

Kelly Davio
Site Logo
December 20th 2017

AJMC®tv Interviews, December 2017

The Center for Biosimilars&reg Laura Joszt, MA
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Insights From Top 5 AJMC.com Contributor Articles of 2017
December 20th 2017

Insights From Top 5 AJMC.com Contributor Articles of 2017

Allison Inserro
Contributors to AJMC.com delved into data to share their knowledge about important topics in managed care, and in 2017, these were the top 5 most-read articles they wrote and published on our online managed care network.
Nat Turner on Using Data for New Payment Model Requirements
December 20th 2017

Nat Turner on Using Data for New Payment Model Requirements

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.
Site Logo
December 20th 2017

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Stanley E. Waintraub, MD Donna McNamara, MD Deena Mary Atieh Graham, MD Andrew L. Pecora, MD John Min, BS Tommy Wu, BA Hyun Gi Noh, MSC Jacqueline Connors, RN, OCN Ruth Pe Benito, MPH, BS Kelly Choi, MD Eric Schultz, BS Stuart L. Goldberg, MD
Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.
Site Logo
December 19th 2017

High-Impact Workflow Changes for Value-Based Care Success

Charles Saunders, MD Charles Alcorn, MS Catherine Cowan, MSN, RN Maria Fabbiano
As oncology practices transition to value-based care, they are challenged to take on more holistic responsibility for their patient. Fortunately, the examples of practices participating in CMS’ Oncology Care Model can offer valuable insight into the most impactful workflow changes providers can implement as they strive to achieve cost and quality improvements.
Site Logo
December 19th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Coverage from the Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.
Site Logo
December 19th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD
Site Logo
December 19th 2017

Stakeholders Weigh in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD
Coverage from the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.
Increased CD8+ TIL Counts Linked to Prolonged Survival in Patients With Certain Ovarian Cancers
December 19th 2017

Increased CD8+ TIL Counts Linked to Prolonged Survival in Patients With Certain Ovarian Cancers

Jaime Rosenberg
Increasing levels of CD8+ tumor-infiltrating lymphocytes are associated with prolonged survival in patients with high-grade serous ovarian cancer, endometrioid ovarian cancer, and mucinous ovarian cancer, according to a study published in JAMA Oncology.
Tesh Khullar on the Importance of Community Oncology Patients Being Involved in Clinical Trials
December 19th 2017

Tesh Khullar on the Importance of Community Oncology Patients Being Involved in Clinical Trials

Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 19th 2017

New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017

Laura Joszt, MA
The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.
Sarcopenia and Inflammation Associated With Increased Risk of Death in Patients with Colorectal Cancer
December 19th 2017

Sarcopenia and Inflammation Associated With Increased Risk of Death in Patients with Colorectal Cancer

Jaime Rosenberg
A study published in JAMA Oncology found that prediagnosis inflammation was associated with at-diagnosis sarcopenia, and the combination of the 2 nearly doubled the risk of death in patients with nonmetastatic colorectal cancer. Because the 2 biomarkers are commonly collected and potentially modifiable, there is potential for clinical use in prognostication and guiding intervention.
The Most-Read News Stories of 2017
December 18th 2017

The Most-Read News Stories of 2017

Laura Joszt, MA
The top 5 most-read news stories included clinical content, such as an FDA approval, and policy news, such as Medicare reimbursement coverage.
Podcast: This Week in Managed Care—CAR T Treatments and Other Health News
December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16th 2017

Diagnosing Non-Chemotherapy Drug-Induced Neutropenia

Laura Joszt, MA
In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.
Average Profit Margin on Oncology Drugs for 340B Hospitals Nears 50%
December 16th 2017

Average Profit Margin on Oncology Drugs for 340B Hospitals Nears 50%

Jaime Rosenberg
"The Oncology Drug Marketplace: Trends in Discounting and Site of Care," commissioned by the Community Onoclogy Alliance and conducted by Berkley Research Group, found that 340B hospitals have a clear financial incentive to expand oncology services; 340B hospitals receive over one-third of all Part B oncology drug reimbursement; a disproportionate share of the shift in site of care is attributable to 340B hospitals; and between 2010 and 2015, statutory discounts and rebates paid by manufacturers have almost tripled and put upward pricing pressure on drugs.
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15th 2017

Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options

Jaime Rosenberg
The majority of women who underwent a lumpectomy or a mastectomy reported not feeling fully informed of their treatment options, but the use of Web-based decision aids can help patients become informed, according to results of 2 new studies published in the Journal of the American College of Surgeons.
5 Key Takeaways From ASH 2017
December 15th 2017

5 Key Takeaways From ASH 2017

Surabhi Dangi-Garimella, PhD
Discussions at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) included progress reports on genetically modified immunotherapy treatments, a new treatment paradigm for advanced Hodgkin lymphoma, possibility of treatment-free remission in chronic myelogenous leukemia, and challenges with hospice utilization for patients with leukemia.
This Week in Managed Care: December 15, 2017
December 15th 2017

This Week in Managed Care: December 15, 2017

This week, the top managed care news included coverage from the 59th American Society of Hematology Annual Meeting and Exposition; recommendations on the use of diabetes drugs with cardiovascular indications; and a new study found that despite changes in insurance plans to give consumers more clout, unnecessary medical spending remains a problem.
Site Logo
December 15th 2017

Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned

Surabhi Dangi-Garimella, PhD
The conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology was that ensuring access to appropriate data and using that information to improve healthcare outcomes remains an ongoing challenge.
Site Logo
December 15th 2017

Lending the Patient Voice to Oncology Quality Measurement

Surabhi Dangi-Garimella, PhD
Speaking at the National Comprehensive Cancer Network Oncology Policy Summit on Redefining Quality Measurement in Oncology, Ronald Walters, MD, MBA, MHA, MS, associate vice president of medical operations and informatics at The University of Texas MD Anderson Cancer Center, emphasized the need to focus on the patient’s preferences and values in cancer care delivery.
Site Logo
December 14th 2017

Report Highlights Increase in Premature Deaths in the United States

Laura Joszt, MA
An analysis of behaviors, community environment, policy, clinical care, and outcomes data has found a disturbing trend in mortality in the United States, with premature deaths, drug deaths, and cardiovascular deaths all increasing.
Site Logo
December 14th 2017

Q&A With Dr Thomas LeBlanc: The Value of ePROs in Oncology

Surabhi Dangi-Garimella, PhD
The FDA has recognized the need to include the patient's voice in the drug development process. The question is: what is the best way to do this?
FDA Announces Public Education Campaign to Encourage Smoking Cessation
December 14th 2017

FDA Announces Public Education Campaign to Encourage Smoking Cessation

Jaime Rosenberg
The FDA has announced its launch of the “Every Try Counts” campaign, which will encourage smokers to quit by advertising messages of support underscoring the health benefits of quitting. The campaign will also focus on celebrating each quit attempt as a step towards success.
<1
...
596061626364656667
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo